Clinical Epidemiology and Global Health

Clinical Epidemiology and Global Health is a gold open access journal published by Elsevier for research on clinical epidemiology and public health in low and middle income countries. Launched in 2013 from New Delhi, it carries studies on disease burden, health services, diagnosis and prognosis, and real world evidence. Its 2025 Journal Impact Factor is 1.9 against a five year value of 2.1.《临床流行病学与全球健康》是 Elsevier 出版的金色开放获取期刊，刊登中低收入国家的临床流行病学与公共卫生研究。该刊 2013 年于新德里创刊，内容涉及疾病负担、卫生服务与真实世界证据。2025 年期刊影响因子为 1.9，五年影响因子为 2.1。

Scope

• The journal's scope centres on clinical epidemiology, meaning the study of the distribution and determinants of health outcomes in patient populations and in the communities they come from.该刊范围以临床流行病学为核心，即研究患者人群及其所在社区中健康结局的分布与决定因素。
• Burden of disease work is a mainstay, with papers estimating incidence, prevalence, disability and mortality for conditions that dominate health systems across South Asia and Africa.疾病负担研究是主要内容，论文估算南亚与非洲卫生体系中占主导地位的疾病的发病率、患病率及伤残与死亡率。
• Health services research appears regularly, covering access, quality, affordability and the organisation of primary care in settings with scarce resources.卫生服务研究经常出现，涉及资源匮乏环境下的可及性、质量与基层照护组织方式。
• Diagnostic accuracy studies and prognostic models are accepted when they report calibration and validation rather than discrimination alone.诊断准确性研究与预后模型需报告校准与验证结果，仅有区分度不足以支撑结论。
• Community and primary care trials, implementation studies and programme evaluations form another strand, with attention to feasibility under routine conditions.社区与基层照护试验、实施性研究与项目评估构成另一条主线，关注常规条件下的可行性。
• Real world evidence from registries, insurance claims and national surveys is welcome, provided the data source and its limitations are described plainly.来自登记系统、医保理赔与全国调查的真实世界证据同样受欢迎，前提是清楚交代数据来源及其局限。
• Health economics papers evaluate cost, cost effectiveness and budget impact of interventions that ministries of health could actually afford to scale.卫生经济学论文评估干预措施的成本、成本效果与预算影响，且这些措施应是卫生部能够真正扩大实施的。
• Maternal, newborn and child health has been a steady presence, reflecting the journal's South Asian origins and the region's neonatal mortality profile.孕产妇、新生儿与儿童健康始终占有一席之地，这与该刊的南亚渊源及该地区新生儿死亡特征相吻合。
• Non communicable disease epidemiology, multimorbidity and ageing receive space alongside infectious disease outbreaks, immunisation coverage and antimicrobial resistance.慢性非传染性疾病流行病学、多病共存与老龄化，与传染病暴发、免疫覆盖及抗微生物耐药并列刊发。
• Environmental and occupational exposures enter through studies of air quality, heat and climate sensitive health outcomes.环境与职业暴露通过空气质量、高温与气候敏感型健康结局的研究进入刊物视野。
• Nutrition, social determinants and health equity are treated as upstream variables, and analyses often stratify by wealth, caste or gender.营养、社会决定因素与健康公平被当作上游变量处理，分析常按财富、种姓或性别分层。
• Surveillance systems and screening programmes are assessed for output, uptake and cost, with implementation detail preferred over efficacy claims alone.监测系统与筛查项目的产出、采纳率及成本受到评估，实施细节优先于单纯的效力宣称。
• Methodological papers on study design and sampling, measurement error and causal inference are considered when the argument carries practical consequences for field research.研究设计与抽样、测量误差与因果推断方面的方法学论文，若能对现场研究产生实际影响，也在考虑之列。
• Evidence translation is part of the remit, so papers that model policy options or estimate the resources needed for scale up sit beside observational studies.证据转化属于刊物职责，模拟政策方案或估算扩大实施所需资源的论文，与观察性研究并列刊发。
• The journal does not restrict itself to one method, accepting qualitative and mixed methods work when it explains why an intervention failed or succeeded.该刊不限定单一方法，定性研究与混合方法研究若能解释干预成功或失败的原因，同样可以发表。

History

• The first volume appeared in 2013 under Reed Elsevier India, with the editorial office in New Delhi and three issues scheduled for that year.首卷于 2013 年由 Reed Elsevier India 推出，编辑部设在新德里，当年计划出版三期。
• Volumes one to three kept a three issue rhythm, a cadence that the National Library of Medicine still records for the title today.第 1 至第 3 卷维持每年三期的节奏，美国国家医学图书馆的刊名记录至今仍沿用这一说法。
• Quarterly publication began with volume four in 2016, when the page budget grew and each issue carried more original research.2016 年第 4 卷起改为季刊，版面容量随之增加，每期原创研究的数量也有所上升。
• Early content was dominated by Indian authors and by studies of tuberculosis, maternal health and health system performance in South Asia.早期稿件以印度作者为主，选题集中在结核病、孕产妇健康与南亚卫生系统绩效。
• Authorship widened through the late 2010s, with corresponding papers arriving from Bangladesh, Nepal, Nigeria and Brazil.2010 年代后期作者来源逐步扩大，来自孟加拉国、尼泊尔、尼日利亚与巴西的稿件明显增多。
• The decisive change came in 2021, when the title became a full author pays open access journal and joined the DOAJ index.决定性变化出现在 2021 年，该刊转为完全由作者付费的开放获取期刊，并进入 DOAJ 索引。
• Two Creative Commons routes are offered, CC BY for unrestricted reuse and CC BY-NC-ND for authors who must block commercial derivatives.刊物提供两种知识共享协议，CC BY 允许不受限制的再利用，CC BY-NC-ND 则供需要阻止商业性演绎的作者选择。
• The same year brought a new serial pattern of one volume per issue and the retirement of issue numbers, and from 2022 the title has run to six volumes a year, so volume 25 opened in January 2024 and volume 30 closed that November.同年起改为一卷一期的编排，卷内期号不再使用，2022 年起固定每年六卷，因此第 25 卷在 2024 年 1 月开卷，第 30 卷于同年 11 月收尾。
• Output grew with the format change, reaching roughly 277 articles a year by 2025, a scale that few public health titles in the region match.编排调整后发文量上升，2025 年前后升至每年约 277 篇，区域内少有公共卫生刊物具备这一规模。
• Indexing followed a two track path, with Emerging Sources Citation Index coverage and selective PubMed deposits rather than full MEDLINE inclusion.收录路径分为两条，刊物进入 Emerging Sources Citation Index，同时向 PubMed 选择性提交记录，尚未被 MEDLINE 完整收录。
• The 2025 Journal Impact Factor stands at 1.9, after 2.3 in 2023 and 1.7 in 2024, while the five year figure is 2.1.2025 年期刊影响因子为 1.9，此前 2023 年为 2.3、2024 年为 1.7，五年影响因子为 2.1。
• Citation totals passed 3,300 by 2025 and a cited half life of 4.1 years points to readers who use current work rather than archival material.到 2025 年被引总量超过 3300 次，4.1 年的被引半衰期说明读者更多使用当期成果，而非回溯旧文。
• Production stayed with Elsevier while editorial decisions remained in New Delhi, a split that keeps local epidemiological judgment close to the manuscripts.生产环节由 Elsevier 承担，编辑决策仍留在新德里，这一分工让本地流行病学判断与稿件保持贴近。

Editors

• Editorial work is organised around an editor in chief supported by associate editors, with the named masthead published on the journal's editorial board page.编辑工作围绕主编展开，由副编辑协助，具名编委名单公布在刊物的编辑委员会页面上。
• All manuscripts enter through Elsevier's online submission system, where a technical check confirms scope fit and completeness before academic assessment starts.所有稿件经 Elsevier 的在线投稿系统进入，先由技术审查确认选题范围与材料完整性，再开始学术评估。
• External referees are chosen for methodological and subject expertise, and reports are expected to address design, sample size justification and analysis rather than tone.外审专家按方法学与主题专长遴选，审稿意见需针对设计、样本量论证与分析，而非文字风格。
• Decisions weigh originality, ethical conduct and usefulness to health systems in resource limited settings, a criterion the journal applies with some consistency.稿件取舍兼顾原创性、伦理规范与对资源有限环境下卫生系统的用处，这也是刊物执行得最一贯的标准。
• Observational studies are expected to follow STROBE reporting, and trial reports must show registration numbers and ethics committee approval.观察性研究需遵循 STROBE 报告规范，试验报告须给出注册号与伦理委员会批准信息。
• Four article formats carry most of the content, namely original articles, review articles, short communications and letters to the editor.刊物以四种栏目承载主要内容，即原创论文、综述、短篇通讯与读者来信。
• Board membership spans epidemiology, biostatistics, health economics and clinical specialties, and members come from institutions in several countries.编委专业覆盖流行病学、生物统计学、卫生经济学与临床专科，成员来自多个国家的机构。
• Review articles are meant to be critical syntheses of a defined question, and authors must state the search strategy and the limits of the evidence.综述要求围绕明确问题做批判性综合，作者须交代检索策略与证据边界。
• Short communications suit negative findings, replication attempts and early signals from surveillance, formats that rarely find room in larger public health journals.短篇通讯适合阴性结果、重复验证与监测系统的早期信号，这类内容在大型公共卫生刊物中往往难以容纳。
• Letters give readers a route to contest published estimates, and corrections or retractions follow the publisher's ethics guidelines with a citable notice.读者来信为质疑已发表估计值提供渠道，更正与撤稿按出版方的伦理准则处理，并发布可引用的声明。
• Language editing and typesetting are handled in house by the publisher, while correspondence with authors stays with the New Delhi editorial office.语言润色与排版由出版方内部完成，与作者的往来则由新德里编辑部负责。
• Conflicts of interest, funding and data availability statements are required at submission, and the declarations are printed with every accepted paper.利益冲突、资助来源与数据可得性声明须在投稿时提交，并在每篇录用论文中随文刊出。